Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana

BACKGROUND: Artemisinin-based combination therapy (ACT) partner drugs, currently used in Ghana are lumefantrine, amodiaquine and piperaquine. Plasmodium falciparum isolates with reduced susceptibility to these partner drugs may affect treatment outcome. Mutations in pfmdr1 gene is linked to reduced...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Malar J
Auteurs principaux: Hodoameda, Peter, Duah-Quashie, Nancy Odurowah, Hagan, Charles Oheneba, Matrevi, Sena, Abuaku, Benjamin, Koram, Kwadwo, Quashie, Neils Ben
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362516/
https://ncbi.nlm.nih.gov/pubmed/32669113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-020-03320-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires